Modulating production of pneumococcal capsular polysaccharide

A pneumococcal, capsular polysaccharide technology, applied to immunogenic preparations administered to animals, production of vaccines, production of pneumococcal polysaccharides, evaluation of whether test compounds can be used to alleviate pneumococcal infection in animals, materials for production of vaccines, relief in animals In the field of pneumococcal infection, it can solve the problem of low yield

Inactive Publication Date: 2003-07-09
THE CHILDRENS HOSPITAL OF PHILADELPHIA
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Existing methods for isolating CPS from p...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modulating production of pneumococcal capsular polysaccharide
  • Modulating production of pneumococcal capsular polysaccharide
  • Modulating production of pneumococcal capsular polysaccharide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0074] The following will be described in conjunction with the following examples. This embodiment is provided for illustrative purposes only, and the present invention is not limited to this embodiment, but on the contrary, the present invention includes all variations that can be derived after reading the specification of the present invention.

[0075] Oxygen dependence of capsular polysaccharide expression in Streptococcus pneumoniae correlates with post-translational modification of CpsD close

[0076] The experiments provided in this example demonstrate that differences in the transparency phenotypes (i.e., O vs. T) among pneumococci are influenced by ambient oxygen concentrations and, such as anaerobic growth conditions that may occur on pneumococci, affect Type O pneumococcus enhances the ability to express CPS and escape immune clearance.

[0077] The materials and methods used in the experiments of this example will be described below.

[0078] Bacterial Stra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a method of assessing whether a test compound is useful for alleviating a pneumococcal infection in an animal. This method comprises comparing (a) the degree of phosphorylation of CpsD in pneumococcal cells maintained in the presence of the test compound and (b) the degree of phosphorylation of CpsD in the same type of cells maintained in the absence of the test compound.

Description

[0001] This research was supported in part by United States Government funds (United States Public Health Service Grant Nos. AI38436 and AI44231), and thus, the United States Government may have certain rights in this invention. Background of the invention [0002] The present invention relates generally to the production of capsular polysaccharide material by Streptococcus organisms and to the production of vaccines from said material. [0003] Streptococcus pneumoniae (sometimes referred to as pneumococcus) is generally a commensal organism that colonizes the mucosal surfaces of the human nasopharynx. When host factors allow the organism to enter the lower respiratory tract, a severe inflammatory response results. Causes a dense consolidation in which the alveolar air spaces are filled with exudate, a symptom commonly referred to as pneumonia (Tuomanen et al., 1995). The most serious manifestation of pneumococcal infection is bacteremia, which may be complicated by sepsis, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/09A61K33/00A61K39/09A61P11/00A61P31/04C12N1/20C12N1/21C12P19/04C12Q1/02C12Q1/18C12R1/46
CPCC12N1/20C12P19/04C12Q1/18A61K39/09A61P11/00A61P31/04C12Q1/02
Inventor J·N·韦泽
Owner THE CHILDRENS HOSPITAL OF PHILADELPHIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products